HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

gadobenic acid (gadobenate dimeglumine)

Subscribe to New Research on gadobenic acid

used in MR imaging of liver

Also Known As:

gadobenate dimeglumine; 3,6,9-triaza-12-oxa-3,6,9-tricarboxymethylene-10-carboxy-13-phenyltridecanoic acid, gadolinium; Altana Pharma brand of gadobenic acid, dimeglumine salt; B 19036; B-19036; Gd-BOPTA; MultiHance; gadobenic acid, dimeglumine salt; gadolinium-BOPTA-Dimeg; gadolinium-benzyloxypropionyl tetraacetate

Networked: 247 relevant articles (23 outcomes, 42 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kirchin, Miles A: 24 articles (12/2015 - 03/2002)
2.	Pirovano, Gianpaolo: 12 articles (09/2015 - 03/2002)
3.	Catalano, Carlo: 12 articles (12/2014 - 10/2005)
4.	Kirchin, M A: 10 articles (09/2015 - 01/2000)
5.	Passariello, Roberto: 10 articles (02/2012 - 10/2005)
6.	Spinazzi, Alberto: 8 articles (09/2015 - 12/2002)
7.	Essig, Marco: 8 articles (06/2011 - 01/2004)
8.	Schneider, Günther: 8 articles (02/2011 - 12/2002)
9.	Pirovano, G: 7 articles (09/2015 - 01/2000)
10.	Pediconi, Federica: 7 articles (05/2014 - 10/2005)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2002 - "Corresponding results with ICP-AES showed significantly greater uptake of Gd-BOPTA in tumor samples than that in peritumoral tissue and normal brain 5 minutes after administration. " 12/01/2015 - "Low-dose gadobenate dimeglumine-enhanced MRI is effective for the differential diagnosis of malignant renal tumors." 11/01/1999 - "MultiHance in the assessment of intracranial tumors: results of phase II clinical studies." 07/01/1996 - "[Early phase II trial of Gd-BOPTA (E7155) for the MR imaging of liver tumors]." 12/01/2015 - "To evaluate low-dose gadobenate dimeglumine-enhanced MRI for the differential diagnosis of malignant renal tumors. "
2.	Neoplasm Metastasis (Metastasis) 01/01/2004 - "The Gd-BOPTA during both dynamic and delayed phases provides valuable information for the characterization of focal liver lesions, and furthermore, Gd-BOPTA-enhanced DPI contributed to the improved detection of liver metastasis compared to precontrast and early dynamic imaging." 05/01/2015 - "The purpose of this prospective study was to test the feasibility for using one of these agents, gadobenate dimeglumine, to detect liver metastases in dogs. " 05/01/2015 - "Feasibility for detecting liver metastases in dogs using gadobenate dimeglumine-enhanced magnetic resonance imaging." 03/01/2011 - "Small colorectal liver metastases: detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging." 03/01/2010 - "To assess the diagnostic performance of gadobenate dimeglumine-enhanced 3D gradient echo (3D-GRE) magnetic resonance imaging (MRI) for the detection of hepatic hypovascular metastases. "
3.	Brain Neoplasms (Brain Tumor) 11/01/1999 - "MultiHance is a safe and effective contrast agent for magnetic resonance assessment of brain tumors when administered intravenously at doses up to 0.2 mmol/kg." 11/01/1999 - "To assess preliminarily the efficacy of 0.1 and 0.2 mmol/kg doses of MultiHance for contrast-enhanced magnetic resonance imaging of brain tumors. " 11/01/2006 - "In this article we review the unique MR imaging properties of MultiHance for the assessment of brain tumors and other cerebral pathologies, and give practical information on how best to optimize MR sequence parameters to achieve the optimal contrast between normal CNS tissue and lesion." 03/01/2006 - "A total of 28 patients with intraaxial brain tumors underwent conventional MR imaging (T2- and T1-weighted sequences after gadobenate dimeglumine injection), diffusion imaging and T2*-weighted echo-planar perfusion imaging. " 06/01/2004 - "MultiHance in brain tumor imaging."
4.	Hepatocellular Carcinoma (Hepatoma) 07/01/2010 - "This study was designed to compare the diagnostic performance of gadoxetic acid-enhanced magnetic resonance imaging (MRI) with gadobenate dimeglumine-enhanced MRI for preoperatively detecting hepatocellular carcinoma (HCC). " 01/01/2006 - "The objective of our study was to compare the diagnostic performance of gadobenate dimeglumine-enhanced MRI with that of 16-MDCT for the detection of hepatocellular carcinoma using receiver operating characteristic (ROC) curve analysis. " 09/01/1999 - "Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: results from phase II and phase III clinical trials in Japan." 07/01/2015 - "Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine." 08/01/2013 - "We evaluated whether the addition of delayed phase imaging (DPI) gadobenate dimeglumine-enhanced MRI to dynamic postcontrast imaging improves the characterization of small hepatocellular carcinoma (HCC) and the differentiation between HCC, high grade dysplastic nodules (HGDN), and low grade dysplastic nodules (LGDN). "
5.	Breast Neoplasms (Breast Cancer) 06/01/2005 - "Gadobenate dimeglumine is effective for MR imaging evaluation of breast vessels at doses as low as 0.05 mmol/kg. One-sided increased vascularity is an MR imaging finding frequently associated with ipsilateral invasive breast cancer." 07/07/2015 - "[Controlled study of gadobenate dimeglumine versus gadopentetate in breast tumor MR dynamic enhancement scanning]." 02/01/2011 - "Readers 1, 2, and 3 reported significantly superior diagnostic performance (sensitivity, specificity, and accuracy) for breast cancer detection with gadobenate dimeglumine (91.1%, 94.5%, 95.2% vs 81.2%, 82.6%, 84.6%; 99.0%, 98.2%, 96.9% vs 97.8%, 96.9%, 93.8%; 98.2%, 97.8%, 96.7% vs 96.1%, 95.4%, 92.8%, respectively; P ≤ .0094) and significantly superior PPV (91.1%, 85.2%, 77.2% vs 80.7%, 75.5%, 60.9%, respectively; P ≤ .0002) and NPV (99.0%, 99.4%, 99.4% vs 97.8%, 98.0%, 98.1%, respectively; P ≤ .0003). " 07/01/2009 - "Two hundred thirty-eight women with dense breast parenchyma who were suspicious for breast cancer or inconclusive for the presence of breast lesions based on clinical examination, ultrasound or x-ray mammography, and who underwent breast MRI at 1.5 T before and after administration of 0.1 mmol/kg gadobenate dimeglumine were evaluated. " 11/01/2007 - "A total of 164 women with suspected breast cancer based on clinical examination, conventional mammography and/or ultrasound each underwent preoperative bilateral CE-MRM using an axial 3D dynamic T1-weighted gradient-echo sequence and gadobenate dimeglumine as contrast agent. "

Related Drugs and Biologics

1.	gadobenic acid (gadobenate dimeglumine)
2.	Gadolinium DTPA (Magnevist)
3.	Gadolinium
4.	Contrast Media
5.	gadobutrol
6.	gadodiamide (Omniscan)
7.	N,N'- bis(pyridoxal- 5- phosphate)ethylenediamine- N,N'- diacetic acid (mangafodipir)
8.	glucuronyl glucosamine glycan sulfate (Vessel)
9.	ferric oxide (iron oxide)
10.	gadolinium ethoxybenzyl DTPA

Related Therapies and Procedures

1.	Renal Replacement Therapy (Therapies, Renal Replacement)
2.	Liver Transplantation
3.	Injections
4.	Intravenous Injections
5.	Endovascular Procedures